T1	Participants 102 221	patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both
T2	Participants 577 707	patients with systolic dysfunction and heart failure receiving therapeutic inhibition of the renin-angiotensin-aldosterone system.
T3	Participants 888 948	768 treated patients with heart failure measured at baseline
T4	Participants 1926 1962	treated patients with heart failure,
